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There is extensive evidence in Parkinson’s disease of a link between oxidative stress and some of the monogenically inherited
Parkinson’s disease-associated genes. This paper focuses on the importance of this link and potential impact on neuronal function.
Basic mechanisms of oxidative stress, the cellular antioxidant machinery, and the main sources of cellular oxidative stress are
reviewed. Moreover, attention is given to the complex interaction between oxidative stress and other prominent pathogenic
pathways in Parkinson’s disease, such as mitochondrial dysfunction and neuroinflammation. Furthermore, an overview of the
existing genetic mouse models of Parkinson’s disease is given and the evidence of oxidative stress in these models highlighted.
Taken into consideration the importance of ageing and environmental factors as a risk for developing Parkinson’s disease, gene-
environment interactions in genetically engineered mouse models of Parkinson’s disease are also discussed, highlighting the role
of oxidative damage in the interplay between genetic makeup, environmental stress, and ageing in Parkinson’s disease.
1. Introduction
Parkinson’s disease (PD) is a highly prevalent neurode-
generative disorder, second to Alzheimer’s disease in terms
of incidence [1]. Its prevalence increases with age, being
approximately 1% in people over the age of 60 and increasing
to about 4% over the age of 85 [2]. It aected about 4.5
million people over the age of 50 in 2005, and by the year
2030, this number will have doubled [3]. The etiology is still
unknown [4], but it is hypothesized that it may result from a
complex interaction between environmental factors, genetic
susceptibility and ageing [5, 6].
Diagnosed patients are characterized by motor and non-
motor clinical manifestations. The motor symptoms include
resting tremor, bradykinesia, akinesia, muscular rigidity, and
a loss of balance [7] and are predominantly attributed to a
lack of dopamine (DA) in the striatum, and the resulting
dysfunction of the basal ganglia, a cluster of nuclei involved
in the initiation and execution of movement [1, 7]. The non-
motor symptoms include impaired olfaction, sleep disorders,
constipation, urinary incontinence, orthostatic hypotension,
and various neuropsychiatric manifestations (e.g., depres-
sion, hallucinations, dementia), and can appear both before
and during the motor symptomatology of PD [7].
The pathological hallmark of PD comprises loss of
nigrostriatal dopaminergic neurons in the substantia nigra
(SN) pars compacta (SNc) and the presence of insoluble
protein inclusions termed Lewy bodies (LBs) and Lewy
neurites (LNs), located in either the neuronal cell bodies
or neuronal processes, respectively [2, 6, 8]. The major
constituent of LBs and LNs is a misfolded version of the
protein alpha-synuclein (α-syn) [8]. There are also non-
dopaminergic neurons aected in PD, leading to more
wide-spread neuronal changes that cause a complex and
heterogeneous clinical picture [7, 9]. Recently, Braak and
colleagues hypothesized a six-stage pathological process in
which PD pathology emerges in the olfactory bulb and
the dorsal motor nucleus of the vagal nerve and only in
later stages extends to the midbrain and other brainstem
regions [10, 11]. Current therapies of PD are symptomatic,
targeting the lack of DA in the striatum with DA replacement
strategies. Although these therapies provide symptomatic
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relief at the beginning, they become gradually inecient as
the disease progresses. Therefore, there is an urgent need of
therapeutic strategies that can tackle the disease progression
[12].
Despite the fact that PD has long been considered as a
non-genetic disorder of sporadic origin, research performed
during the past decade has led to the identification of genes
linked to rare monogenic forms of PD. This resulted in the
identification of 16 “PARK” loci, with the autosomal domi-
nant genes SNCA (PARK1/4), and LRRK2 (PARK8), and the
autosomal recessive genes parkin (PARK2), DJ-1 (PARK7),
and PINK1 (PARK6) being the most common ones [2, 3, 5].
Although monogenic forms account for <10% of PD cases,
these genes also play a role in the much more common
sporadic form of the disease [5]. Unraveling the molecular
mechanisms underlying the familial forms of PD will con-
tribute to our understanding of sporadic PD, since both share
clinical and neuropathological features [5]. Moreover, several
cellular abnormalities which may underlie the neurodegen-
eration displayed in sporadic PD, such as mitochondrial
dysfunction, oxidative stress, excitotoxicity, proteasomal
stress, neuroinflammation, and protein aggregation, are
also associated with mutations in the familial PD genes
[13, 14].
Multiple animal models have been developed in order to
study the pathogenesis and progression of PD and to test
potential therapeutic strategies [15]. Currently, focus is being
put on integrating genetic, environmental, and age-related
influences in more relevant preclinical animal models, which
can reproduce PD pathology with high fidelity.
Since there is extensive evidence of oxidative stress in
the pathogenesis of PD [14, 16–20], and a link between
oxidative stress and some of the monogenically inherited PD
associated genes has been described, this paper focuses on its
importance and potential impact on neuronal function. It is
interesting that despite all the evidence for a role of oxidative
stress in PD, there have been relatively few studies that have
extensively characterized oxidative stress in animal models of
PD [21]. In this paper, an overview is given of oxidative stress
findings in monogenic mouse models of PD. In addition, a
focus will be put on gene-environment interactions in these
mouse models.
2. Genetic Forms of Parkinson’s Disease
The PD genes can show both recessive and dominant modes
of inheritance. The autosomal dominant PD genes include
SNCA, leucine-rich repeat kinase 2 (LRRK2), microtubule-
associated protein tau (MAPT), Htr serine peptidase 2
(HtrA2), and glucocerebrosidase (GBA), while the autoso-
mal recessive PD genes include parkin, PTEN-induced kinase
1 (PINK1), and DJ-1 [5, 22]. In the context of this paper,
only SNCA, parkin, PINK1, and DJ-1 are discussed in further
detail.
Studies of PD-linked genes have brought to light several
pathways involved in neuronal death in the SNc (protein
aggregation, defects in the ubiquitin-proteasomal pathway,
impaired defense against oxidative stress, abnormal protein
phosphorylation, mitochondrial and lysosomal dysfunction,
apoptosis), thus improving our understanding of the more
common sporadic form of the disease. “Sporadic” cases may,
in fact, be monogenic as well, because mutations may have
occurred de novo [5].
2.1. SNCA. The SNCA gene encodes α-syn, a small 140
amino acid protein that can be both lipid associated and free
in the cytoplasm [23]. It has been shown that α-syn promotes
PD pathogenesis either by dominantly inherited mutations
in the SNCA gene (A30P, A53T, and E46K) or by factors
that enhance α-syn expression, such as gene multiplication
(e.g., duplication, triplication) of the SNCA gene or by SNCA
promoter polymorphisms that increase α-syn expression [2,
7]. Although the three missense mutations in SNCA are very
rare, a normal expression of a mutant form of α-syn, or
overexpression of the wild-type (WT) α-syn, can contribute
to the pathogenesis of PD [2]. Furthermore, a clear evidence
for an SNCA dosage eect was also revealed in one familial
case of PD [2].
The phenotype of patients with SNCA mutations resem-
bles sporadic PD, but with earlier onset and atypical features,
including cognitive decline, psychiatric problems, and auto-
nomic dysfunction. The same mutations have been found in
sporadic PD patients, suggesting significant frequency of de
novo mutations [5].
2.2. Parkin. Parkin is a 465 amino acid E3 ubiquitin ligase,
which transfers ubiquitin to target proteins for degradative
(i.e., via the proteasome system) or non-degradative (i.e.,
signaling) purposes. Mutations in parkin account for the
majority of early-onset familial PD cases [24]. Loss-of-
function of parkin can contribute to the etiology of PD
either by disrupting the normal function of the ubiquitin
proteasome system (UPS) in the clearance of aggregated
proteins or by disabling a mitochondrial protective mecha-
nism mediated by parkin’s signaling function, contributing
to mitochondrial dysfunction [24].
2.3. PINK1. PINK1 encodes a 581 amino acid serine/threo-
nine kinase that is localized to the mitochondria. Mutations
in PINK1 are the second most common cause of autosomal
recessive early-onset familial PD after parkin, with most
mutations occurring in and disrupting the activity of the
kinase domain [18, 24, 25]. As with parkin, loss-of-function
of PINK1 leads to decreased mitochondrial protection
against oxidative stress, causing enhanced mitochondrial
dysfunction [26]. Although the biological function of the
PINK1 protein is not fully understood, studies show an
important role in the maintenance of mitochondrial func-
tion and protection against oxidative stress [27–30].
2.4. DJ-1. DJ-1 encodes a 189 amino acid protein of still-
uncertain function. Mutations in DJ-1 represent a rather
rare cause of early-onset familial PD [24]. Still, insights
into putative roles of DJ-1 brought this protein under
investigation, and it seems that DJ-1 is involved alongside
parkin and PINK1 in protecting the mitochondria against
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oxidative stress [7]. Interestingly, reduced DJ-1 expression is
also associated with proteasome inhibition [23], highlighting
an additional role of DJ-1 in the normal function of the UPS.
The DJ-1 protein was found to be oxidatively damaged and
significantly increased in brains of sporadic PD patients [5].
Patients carrying a mutation in parkin, PINK1, or DJ-1
show marked clinical overlap, generally suering from
early-onset parkinsonism with a slower disease progression,
good levodopa response, and early development of motor
fluctuations [2].
3. Oxidative Stress in Parkinson’s Disease
Oxidative stress can be defined as a condition in which the
cellular antioxidant defense mechanisms are insucient to
keep the level of reactive oxygen species (ROS) below a toxic
threshold [7]. This may be either due to an overproduction
of reactive free radicals or to a failure of cell buering
mechanisms [14]. ROS can damage all types of biomolecules,
and oxidative damage to nucleic acids, lipids, and proteins
can be deleterious [31]. Several of the genes linked to familial
forms of PD appear to be involved in the protection against
or in the propagation of oxidative stress [14, 32]. Further-
more, oxidative stress and mitochondrial dysfunction have
been linked to the pathogenesis of PD, ever since exposure
to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a
complex I inhibitor, was found to induce parkinsonism
in humans [30, 33]. Data from postmortem studies of
brains from patients with PD (Table 1) suggest that oxidative
stress plays an important role in neuronal degeneration
of the dopaminergic nigral neurons [34, 35]. Early and
profound loss of glutathione (GSH) levels, a reduction
in mitochondrial complex I activity, increased oxidative
damage to lipids, proteins, and DNA, increased superoxide
dismutase (SOD) activity, and elevated free iron levels in
the SN of PD patients have been demonstrated [9, 15, 35–
39]. Moreover, in vivo observations (Table 1) demonstrated
that several markers of oxidative stress are altered in the
cerebrospinal fluid (CSF) and blood samples of PD patients
[40, 41].
Nevertheless, it should be noted that many clinical trials
are done in chronically treated PD patients, and drug intake
may influence the outcome of the study. For instance, a well-
described eect of chronic levodopa intake is the elevation of
the homocysteine plasma levels, which is a risk factor for var-
ious pathological conditions possibly due to homocysteine-
mediated increase in oxidative stress [47–50]. Furthermore,
Buhmann et al. [43] have shown that levodopa monotherapy
results in an increase in auto-oxidation and in a decrease
of plasma antioxidants with significance for ubiquinol-10,
while DA agonist monotherapy was associated with higher
alpha-tocopherol levels [43]. Mu¨ller and Muhlack [48]
have also shown that acute levodopa/carbidopa application
reduces free cysteine/glycine levels in plasma and that this
decline may be linked to prior appearance of oxidative stress
with concomitant consumption of antioxidants like GSH and
subsequent conversion of this molecule to oxidized GSH
(GSSG) [48]. Therefore, the study design of the clinical trial
should be carefully considered when investigating oxidative
stress in PD patients.
It is interesting to note that the brain in particular is more
vulnerable to oxidative stress and oxidative damage com-
pared to other organs. For instance, the brain consumes more
oxygen on a per weight basis under physiological conditions
than any other organ, thereby increasing its susceptibility
to oxidative stress. Also, the brain contains a relatively low
level of antioxidants and free radical scavenging enzymes
compared to other tissues [51–53], as well as a high amount
of substances, such as phospholipids and unsaturated fatty
acids, which are vulnerable to oxidative modifications [33,
54]. Indeed, markers of lipid peroxidation, such as elevated
4-hydroxynonenal (4-HNE) and malondialdehyde (MDA),
have been observed in postmortem brain tissue and CSF of
PD patients [42, 51]. Moreover, the vulnerability of neurons
to oxidative damage, which accumulates in ageing neurons,
might also be due to their postmitotic nature [55].
ROS are produced by a number of dierent pathways,
including direct interactions between redox-active metals
and oxygen species via reactions such as the Fenton and
Haber-Weiss reactions, or by indirect pathways involving
activation of enzymes, such as nitric oxide synthase (NOS).
All the initial free radical reactions require activation of
molecular oxygen [51]. It is important to realize that ROS
are being continuously generated in vivo as a result of oxygen
metabolism, with about 1–5% of the oxygen consumed being
converted to ROS [30]. The univalent reduction of molecular
oxygen leads to the formation of superoxide anion (O2
•−),
hydrogen peroxide (H2O2), and hydroxyl radicals. The O2
•−
can lead to the generation of hydroxyl radicals via Fe2+
catalyzed Haber-Weiss and Fenton reactions. The generation
of reactive nitrogen species (RNS) is due to NOS-mediated
conversion of arginine to citrulline and the subsequent
generation of nitric oxide (NO), which reacts with O2
•− to
produce peroxynitrite (ONOO−) [51].
The high concentration of DA in the nigrostriatal
pathway is presumed to be an essential determinant for
the high vulnerability of dopaminergic cells to oxidative
stress. DA itself does not exert direct toxic eects, but
toxic intermediates derived from its catabolism [54] may
contribute to the oxidative stress pathogenic pathway in PD.
The catabolism of DA includes auto-oxidation into toxic DA-
quinone species, O2
•− and H2O2, and the enzymatic conver-
sion via monoamine oxidase B (MAO-B) into the inert 3,4-
dihydroxyphenylacetic acid (DOPAC) and H2O2 [56]. Fur-
thermore, the H2O2 and O2
•− produced by DA catabolism
can be further converted into highly toxic hydroxyl radicals
as described above [17, 36]. It is important to note that these
hydroxyl radical generating pathways are heavily dependent
on the presence of iron, which have been found to be elevated
in the SN of PD patients [36]. The particular reason for this
is not yet understood, but it seems to be related with the
age-dependent accumulation of neuromelanin in the nigral
neurons [51]. Neuromelanin is a dark-brown pigment that
concentrates metal ions, in particular iron, and that makes
the nigrostriatal dopaminergic neurons seem dark colored.
The age-dependent accumulation of neuromelanin will lead
to a higher local concentration of iron in dopaminergic
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Table 1: Oxidative stress parameters in Parkinson’s disease patients.
Observation Marker for oxidative stress Sampled region Outcome (versus control) References
In vivo MDA Blood, CSF ↑ [40]
GSH reductase Blood ↑
Cu/Zn-SOD Blood ↑
Superoxide Blood ↑
In vivo HNE Plasma, CSF ↑ [42]
In vivo Lipoprotein oxidation Plasma, CSF ↑ [43]
Protein sulfhydryl groups Plasma, CSF ↓
α-Tocopherol CSF ↓
In vivo Cu/Zn/Mn-SOD activity Skin fibroblasts ↔ [44]
GPx activity Skin fibroblasts ↔
Catalase activity Skin fibroblasts ↔
In vivo Lipid oxidation products Plasma ↑ [19]
8-OHdG Urine ↑
In vivo Markers of oxidative stress iPSCs ↑ [45]
Sensitivity to oxidative stress iPSCs ↑
In vivo MDA Blood ↑ [41]
SOD activity Blood ↑
GPx Blood ↔
Postmortem Lipid peroxidation SN ↑ [38]
Reduced GSH SN ↓
Total iron SN ↑
Ferritin SN ↓
GPx activity SN ↓
Catalase activity SN ↓
Postmortem Iron SN ↑ [39]
MAO-B SN ↑
Cu/Zn-SOD SN ↑
Heme oxygenase SN ↑
GSH SN ↓
Vitamin C SN ↓
Postmortem GPx 4 SN ↑ [46]
Postmortem Protein oxidation Caudate nucleus ↑ [35]
Lipid peroxidation Frontal cortex ↑
Protein nitration
Caudate nucleus, putamen,
frontal cortex
↔
Total GSH
Caudate nucleus, putamen,
frontal cortex
↑
Catalase
Caudate nucleus, putamen,
frontal cortex
↔
SOD
Caudate nucleus, putamen,
frontal cortex
↔
GSH reductase
Caudate nucleus, putamen,
frontal cortex
↔
GPx Caudate nucleus, putamen ↑
Abbreviations: 4-HNE: 4-hydroxynonenal, 8-OhdG: 8-hydroxydeoxyguanosine, CSF: cerebrospinal fluid, GPx: GSH peroxidase, GSH: glutathion, iPSCs:
induced pluripotent stem cells, MDA: malondialdehyde, SN: substantia nigra, SOD: sodium dismutase, ↑: increased, ↓: decreased, ↔: not dierent.
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neurons, and this will expose the neurons to increasing
concentrations of highly toxic hydroxyl radicals. Moreover,
several studies have indicated that one of the consequences
of normal aging is the increase in the concentrations of
copper and iron in brain tissue [51]. Due to this, the current
view is that the hydroxyl-radical-mediated oxidative stress
induced by dysregulation in the neuromelanin and iron
homeostasis is one of the most important contributors to
the oxidative damage in PD [17, 36, 51]. The generation of
ROS also initiates excitotoxicity, which is modulated by the
overactivation of N-methyl-D-aspartate (NMDA) receptors
[51]. In response to activation of the NMDA receptors, NO is
produced, due to the interaction of NOS with these receptors
[54].
Numerous studies have reported the involvement of
mitochondria, neuroinflammation via activated microglia,
and other ROS-mediated pathways in the pathogenesis of
PD.
3.1. Impaired Mitochondrial Function. Several lines of evi-
dence, some obtained from PD patients, indicate that the
mitochondrial dysfunction plays a major role in the patho-
genesis of PD, with defects in complex I of the mitochondrial
electron chain transport gaining the most attention [9, 57,
58]. Complex I is located in the inner mitochondrial mem-
brane and constitutes a part of the oxidative phosphorylation
system responsible for the generation of cellular adenosine-
5′-triphosphate (ATP) [59, 60]. Mitochondria exert both
vital and lethal functions in physiological and pathological
conditions. On the one hand, they are indispensable for
energy production and hence for the survival of eukaryotic
cells; on the other hand they are crucial regulators of the
intrinsic pathway of apoptosis [61]. Furthermore, mitochon-
dria are main sources of ROS in the central nervous system
(CNS) [62]. Mitochondria contain redox carriers that can
transfer single electrons to oxygen, thus generating O2
•−.
Enzymes in the tricarboxylic acid cycle and the electron
transport chain (complexes I, II and III) and MAOs are
among the mitochondrial carriers generating O2
•−. The
generated O2
•− can be converted by the cellular defense
mechanism into H2O2, which further can react with other
molecules, as described above [30, 62].
An impairment of normal mitochondrial function leads
to an excessive production of ROS and a general decrease
in ATP levels. Furthermore, there is a concomitant loss
of mitochondrial membrane potential [63]. Under physi-
ological conditions, mitochondria harbour a robust mito-
chondrial transmembrane potential and a low-conductance
state of the permeability transition pore complex (PTPC)
might contribute to exchange of small metabolites between
the cytosol and the mitochondrial matrix, a process that
is mainly controlled by mitochondrial solute carrier. In
response to proapoptotic stimuli, such as ROS and calcium
(Ca2+) overload, the PTPC assumes a high conductance state
that allows the deregulated entry of small solutes into the
mitochondrial matrix along their electrochemical gradient.
This phenomenon, which is known as mitochondrial per-
meability transition, results in the immediate dissipation of
the mitochondrial membrane potential and osmotic swelling
of the mitochondrial matrix. As a consequence, this may
lead to mitochondrial outer membrane permeabilization
and to the release into the cytosol of cytotoxic proteins
normally confined within the mitochondrial intermembrane
space. The cytotoxic proteins include caspase activators,
such as cytochrome c and DIABLO, as well as caspase-
independent cell death eectors like apoptosis-inducing
factor and endonuclease G [61, 63].
Next to being the main source of free radicals and having
a role in the electron transport chain and oxidative phos-
phorylation, the mitochondria are also involved in Ca2+
homeostasis [9]. Mitochondria are known to play an impor-
tant role as Ca2+ buer, thereby preventing sustained high
cytosolic Ca2+ levels, via the uptake of these ions through
a membrane potential-dependent uniporter [64]. Saturation
of this buering system can be prevented, by releasing
mitochondrial Ca2+ again into the cytosol via the H+/Ca2+
exchanger and a yet unidentified Na+/Ca2+ exchanger [65].
3.2. Neuroinflammation. The neurotoxicity associated with
inflammatory processes in the CNS seems to be mainly medi-
ated by overactive microglia [66]. Microglia are components
of the CNS innate immune system, normally display a resting
phenotype, and only become activated upon brain injury
or immune challenge [66]. In relation to oxidative stress,
microglia have been identified as an important source of
ROS [62]. Microglia, which are phagocytic cells, have a dual
role in the CNS. They can be either neuroprotective through
the elimination of exogenous and endogenous substances or
promote neurodegeneration by producing potentially toxic
agents [66–68]. Overactive microglia were shown to release
toxic compounds to dopaminergic cells, such as O2
•−, H2O2,
and NO, as well as proinflammatory cytokines, such as the
tumor necrosis factor-alpha (TNF-α) and interleukin-1β (IL-
1β) [69, 70], and it is currently well known that microglial
activation results in dopaminergic cell death in PD patients
[71]. O2
•−, released by overactive microglia, seems to be
the critical mediator of cell death [71]. Its production is
mediated by the NADPH oxidases, which comprise several
multicomponent enzyme complexes, that transfer electrons
across biological membranes [62, 71–73]. Although the
major source of NADPH oxidase induced oxidative stress
is of activated microglia, NADPH oxidases from neuronal
origin might also contribute to cell death [74]. The activation
of NADPH oxidase is also mediated via interactions between
the dopaminergic system and the central renin-angiotensin
system [75]. We recently showed that stimulation of central
angiotensin 1 (AT1) receptors leads to the activation of
NADPH oxidase, while stimulation of central AT2 receptors
leads to inhibition of NADPH oxidase activation [75, 76].
Factors driving microglial overactivation in PD might be
linked to environmental toxins, endogenous disease proteins,
and even the neurodegenerative process itself. Indeed, it was
shown that PD toxins such as MPTP, rotenone, paraquat,
and particulate matter from polluted air are potent inducers
of microglial activation, suggesting environmental triggers in
PD [66].
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Lastly, dopaminergic cell death releases proteins in the
extracellular space, such as histones, oxidized lipids, DNA,
and ATP, that are interpreted by microglial cells as damage-
associated molecular pattern molecules, leading to their
activation [77]. This finding is particularly interesting, as it
implies that neuronal cell death, which may be increased
by microglial neurotoxicity, further reinforces the overactive
phenotype of the microglia. This would create a self-
perpetuating neurotoxic cycle, whereby microglial cells are
capable of enhancing neurodegeneration, while this in turn
would further enhance microglial activation [66]. Such a
cycle would be particularly damaging to dopaminergic neu-
rons in the SN, as it contains 4.5 times more microglial cells
compared to other areas of the brain [71].
Understanding the role of oxidative stress as a primary
event in the pathogenesis of PD is complicated, as dierent
pathways themselves can play a primary role and, in turn
can initiate the formation of ROS/RNS. The above findings
demonstrate how complex the interaction between oxidative
stress, mitochondrial impairment, and neuroinflammation
is, making it problematic to determine which occurs first.
Furthermore, impairment in the UPS system, which is the
primary mechanism responsible for eliminating mutant,
damaged, and misfolded intracellular proteins, and for
regulating the levels of short-lived proteins, can result in the
accumulation of abnormal proteins, leading to the disrup-
tion of the cellular homeostasis and integrity, and creating
a state referred to as proteolytic stress [78]. Again, oxidative
stress may contribute to this impairment, and in turn, UPS
impairment can induce oxidative stress [17].
3.3. Cellular Antioxidant Mechanisms. To maintain a proper
redox balance, all aerobic organisms utilize series of sophis-
ticated antioxidant defense mechanisms in an attempt to
protect themselves against oxidative damage by eliminating
ROS, thereby balancing the ratio between generation and
detoxification of ROS. Numerous antioxidant enzymes, such
as catalases, SOD, peroxiredoxins, and GSH peroxidase
(GPx), and low-molecular weight compounds such α-
tocopherol, ascorbic acid, and GSH have been characterized
[31, 37, 79, 80]. The removal of H2O2 is accomplished by
two enzyme families: GPx and catalases, both reducing it
to oxygen and water. GPx utilizes the power of reduced
GSH that is converted, via reduction of H2O2, to oxidized
GSH [79]. The continuous action GPx is permitted by
GSH reductase that recycles reduced GSH from its oxidized
form. Another enzyme, quinone reductase, catalyzes the
direct divalent reduction of quinones to quinols and avoids
the formation of reactive semiquinone radical intermediates
[79]. Furthermore, two nonenzymatic proteins, ferritin and
ceruloplasmin, have an important role in transition metal
storage [79].
In addition, a rise in ROS may also constitute a stress sig-
nal that activates redox-sensitive signaling pathways, which
once activated may have either damaging or potentially
protective functions [80]. The major signaling pathways
activated in response to oxidative stress are the extracellular
signal-regulated kinase (ERK), c-Jun N-terminal kinase
(JNK), phosphoinositide 3-kinase [PI(3)K]/protein kinase
B (AKT), nuclear factor kappa B (NFκβ), p53 and p38
pathways. NFκβ and p53 are transcription factors, while
PI(3)K/AKT and mitogen-activated protein kinase (MAPK)
pathways regulate transcription factors through phospho-
rylation. The degree to which a given pathway is activated
is highly dependent on the nature and on the duration of
the stress [80]. Furthermore, the activation of peroxisome
proliferator-activated receptors (PPAR), whose natural lig-
ands are polyunsaturated fatty acids and their oxidation
products, may be involved in the pathogenesis of PD. PPAR
is also considered as a regulator of mitochondrial biogenesis
genes that upregulates genes known to protect against oxida-
tive stress [81]. Numerous protective genes, such as heme-
oxygenase, have been shown to be inducible in mammalian
cells following exposure to oxidative stress [79]. The exact
ROS sensing mechanisms are not well understood, but a
number of transcription factors that regulate the expression
of antioxidant genes are well characterized [37]. Major
signaling pathways activated in response to oxidative stress
include (i) transcription factors, such as NFκb, activator
protein 1 (AP1), and antioxidant response elements (AREs)
binding proteins that can interact directly with specific DNA
motifs on promotors of target genes (ii) or via MAPK
cascades, which in turn activate transcription factors that
trigger target gene transcription [82]. The transcription of
the cytoprotective proteins is under control of the nuclear
transcription factor NF-E2-related factor 2 (Nrf2). Upon
normal homeostatic conditions, Nrf2 is repressed by its
negative regulator Keap1. Upon exposure to ROS, Nrf2
dissociates from cytosolic Keap1 and translocates to the
nucleus, where it binds to the AREs in the promoter region of
the genes encoding antioxidant enzymes [37]. These findings
suggest that an increase in ROS results in two critical eects:
(i) damage to cell components via an excessive production
of ROS and also (ii) activation of specific signaling pathways
regulated via ROS, influencing various cellular processes
leading either to cell death or to proper cell function [82, 83].
Mitochondria are highly dynamic organelles that can
undergo repeated cycles of fusion and fission to regulate
their shape and length, and to control the total number of
mitochondria per cell. The fusion of two mitochondria serves
as a protective mechanism by forming tubular networks,
leading to the exchange of lipid membranes, mitochondrial
DNA (mtDNA), and soluble metabolites to compensate for
individual deficiencies, as well as to the dilution of toxic
intermediates, such as ROS. On the other hand, mito-
chondrial fission allows division and sequestration of dam-
aged parts of this organelle by autophagy [84]. Several levels
of defense mechanisms have been shown in mitochondria
to ensure their integrity. A first line of defense comprises
molecular chaperones, which assist folding and assembly
of mitochondrial proteins and prevent oxidative-stress-
mediated mitochondrial injury. A second protective mech-
anism involves the degradation of damaged proteins by
mitochondrial proteases [85]. However, once the mito-
chondrial quality control is overwhelmed, a third pathway
is activated and induces selective autophagic clearance of
damaged mitochondria (mitophagy) [85–87].
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4. Evidence of Oxidative Stress in Genetic
Animal Models of Parkinson’s Disease
A better understanding of the pathophysiology of PD is
only possible with the development of reliable experimental
models, which can mimic disease processes with good
fidelity. Initially, PD was modeled by administration of
neurotoxins, such as 6-hydroxydopamine (6-OHDA) and
MPTP. However, the identification of PD-associated genes
has led to the development of new genetic animal models
of PD [88]. While many models have been created, to date
no single model, either based on toxins or genetics, has
been able to recreate all the key features of the disease [89].
Nevertheless, knockout (KO), knockdown (KD), knock-in,
overexpression, and/or mutations in single genes provide
a powerful tool to study the etiology of PD [89]. Thus
far, several genetically engineered animal models of PD
have been generated [55, 90]. Transgenic systems are widely
used to study the cellular and molecular basis of human
neurodegenerative diseases. A wide variety of model organ-
isms have been utilized, including bacteria (Escherichia coli),
nematodes (Caenorhabditis elegans), arthropods (Drosophila
melanogaster), fish (zebrafish, Danio rerio), and rodents
(mouse, Mus musculus and rat, Rattus norvegicus), as well
as nonhuman primates (rhesus monkey, Macaca mulatta).
These transgenic systems have enormous value for under-
standing the pathophysiological basis of disorders and have,
in some cases, been instrumental in the development of
therapeutic approaches to treat these conditions [91]. Once
a causative mutation has been identified, transgenic systems
can be generated to model the human disease or aspects
of the altered gene function. All the models can provide
further confirmation of the genetic basis of the disease and
contribute to the identification of cellular and molecular
mechanisms responsible for the disease phenotype. The
available transgenic models vary in terms of easiness of
manipulation and phylogenetic relatedness to humans, but
have all been useful for the study of neurodegenerative dis-
eases [91].
Among the invertebrate systems, the arthropod fruit
fly Drosophila melanogaster and the nematode worm
Caenorhabditis elegans have been the most widely used. The
advantage of using invertebrates is their rapid production
and analysis of transgenic lines expressing variants of disease-
associated proteins. A disadvantage is that they lack critical
factors, such as immune function and myelination [91, 92].
Despite the notable advances that have occurred in the
above-mentioned species, the mouse remains the most
widely used system for modeling human neurodegenerative
diseases, since it is closely related to humans and oers
advantages such as the relatively low cost, short generation
time, high-environmental control, and the possibility for
genome manipulation that allow virtually any disease-
associated genetic alteration in humans to be introduced into
the mouse [91].
Since, as described above, there is a prominent role for
oxidative stress in the pathogenesis of PD, while deficiencies
in products of several PD-associated genes, including SNCA,
parkin, PINK1, and DJ-1, may be linked to increased
oxidative stress and/or higher vulnerability to oxidative
damage, an overview is given of several oxidative stress
hallmarks that have been observed within these genetically
modified animal models of PD, with an emphasis on the
mouse models (Table 2).
4.1. DJ-1 Models. No significant dierences were detected in
protein nitration, nucleic acid oxidation, and lipid peroxida-
tion in the SN of aged DJ-1 KO mice [95]. Similarly, protein
oxidation was not altered in the whole brain of DJ-1 KO
mice at dierent ages [93, 94]. These findings demonstrate
that DJ-1 KO does not lead to increased oxidative damage
in basal conditions [93–95]. Nevertheless, several groups
observed increased mitochondrial ROS levels in the SN as
well as in the whole brain, of DJ-1 KO mice at dierent ages
[94, 96]. Furthermore, decreased mitochondrial aconitase
activity was described in young, but not in aged KO mice
[94]. It is interesting to note that although Andres-Mateos
et al. [94] observed a 2-fold increase in the mitochondrial
H2O2 production in DJ-1 KO brains, the mice did not show
any dopaminergic degeneration or mitochondrial damage.
They did note, however, that compensatory mechanisms
(upregulation of MnSOD and GPx levels and increase in GPx
activity) have been activated to compensate for the elevated
H2O2 in mitochondrial, but not in cytosolic fractions from
aged mice. These compensatory increases in GPx levels
and activity appear to compensate for the lack of DJ-1
because the cytosolic levels of reduced GSH and GSSG
and the ratio GSSG/GSH in DJ-1 KO brains do not dier
significantly compared with their respective WT littermates
[94]. These results taken together suggest that the absence
of DJ-1 leads to an increase in mitochondrial H2O2 and a
compensatory increase in mitochondrial GPx activity in aged
DJ-1 KO mice, suggesting that DJ-1 plays an important role
in mitochondrial elimination of H2O2 [94]. Furthermore,
the decreased mitochondrial aconitase activity (an enzyme
which is highly sensitive to ROS), as a consequence of
an increase of mitochondrial H2O2 production, was only
detected in young DJ-1 KO mice, and not in aged mice that
showed an increased expression in GPx [94].
Recently, Guzman et al. [96] have shown, using trans-
genic mice that expressed a redox-sensitive variant of green
fluorescent protein targeted to the mitochondrial matrix,
that the engagement of plasma membrane L-type Ca2+
channels during normal autonomous pacemaking created
an oxidative stress that was specific to the nigral neurons,
and that the oxidative stress engaged defenses that induced
transient, mild mitochondrial depolarization or uncoupling.
This demonstrates that in mature SNc dopaminergic neu-
rons a basal mitochondrial oxidant stress is present, and
that the oxidative stress is not a consequence of old age,
pathology, or the experimental preparation, but rather one of
a neuronal design that engages L-type Ca2+ channels during
autonomous pacemaking. Furthermore, SNc dopaminergic
neurons lacking DJ-1 were shown to have an elevation in
mitochondrial oxidative stress, and additional experiments
confirmed that this was not due to lowered expression of
antioxidant enzymes, but rather to diminished levels of
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Table 2: Oxidative stress parameters in transgenic mouse models of Parkinson’s disease.
Model Age (mo.) Marker for oxidative stress Sampled region Technique Outcome (versus control) References
DJ-1 KO 5, 11 Protein oxidation Entire brain Oxyblot ↔ [93]
DJ-1 KO 2-3,18–24 Protein oxidation Entire brain Oxyblot ↔ [94]
Mitochondrial ROS Entire brain Amplex red assay ↑
Mitochondrial aconitase activity Entire brain
Mitochondrial aconitase activity
assay
↓ at 2-3 mo., ↔ at 18–24 mo.
DJ-1 KO 24–27 DNA/RNA oxidation SN IHC ↔ [95]
Nitrotyrosine SN IHC ↔
4-HNE SN IHC ↔
DJ-1 KO 1 Mitochondrial ROS SN 2PLSM ↑ [96]
Mn-SOD SN RT-qPCR ↔
GPx SN RT-qPCR ↔
Catalase SN RT-qPCR ↔
DJ-1 KO 4–6 Mitochondrial ROS Entire brain PHPA assay ↑ [97]
Parkin KO 22 Protein oxidation Striatum, cortex Oxyblot ↔ [98]
Parkin KO 11 Total GSH Striatum Method of Tietze ↑ [99]
GSSH Striatum Method of Grith ↔
Parkin KO 8 Peroxiredoxin 1 Ventral midbrain 2DGE + MS ↓ [100]
Peroxiredoxin 2 Ventral midbrain 2DGE + MS ↓
Peroxiredoxin 6 Ventral midbrain 2DGE + MS ↓
Lactoylglutathione lyase Ventral midbrain 2DGE + MS ↓
3, 6, 18 4-HNE Brain IHC ↔ at 3 or 6 mo., ↑ at 18 mo.
5–12 Total antioxidant capacity Serum Serum antioxidant capacity assay ↓
3, 18–20 Protein oxidation Entire brain Oxyblot ↔ at 3 mo., ↑ at 18–20 mo.
Parkin KO 2, 12 Mitochondrial aconitase Striatum, cortex 2DGE + MS ↑ in cortex at 2 mo. [101]
GSH S-transferase P 2 Striatum, cortex 2DGE + MS ↓ in striatum and cortex at 2 mo.
Carbonyl reductase [NADPH] 1 Striatum, cortex 2DGE + MS ↑ in striatum at 2 mo.
Lactoylglutathione lyase Striatum, cortex 2DGE + MS ↑ in striatum at 2 mo.
Thioredoxin reductase Striatum, cortex 2DGE + MS ↑ in striatum at 2 mo.
Protein oxidation Striatum, cortex Oxyblot ↔
Parkin KO 2, 24 Total GSH Striatum, midbrain, limbic system Method of Tietze ↑ at 2 mo., ↓ at 24 mo. [102]
GSH reductase activity Striatum, midbrain, limbic system GSH reductase activity assay
↔ (within KO group, ↑ at 24 mo. versus
2 mo.)
GPx activity Striatum, midbrain, limbic system Method of Flohe and Gunzler
↔ (within KO group, ↑ at 24 mo. versus
2 mo.)
Catalase activity Striatum, midbrain, limbic system
Reaction with methanol in pres-
ence of H2O2
↔
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Table 2: Continued.
Model Age (mo.) Marker for oxidative stress Sampled region Technique Outcome (versus control) References
Parkin KO 19–21 Nitrotyrosine SN ELISA ↑ [103]
Nitrated α-synuclein SN IHC Only KO stain positive
PINK1 KO 3-4 Lipid peroxidation Striatum, cortex TBARS levels ↔ [29]
24 Protein oxidation Striatum Oxyblot ↔
4-HNE SN IHC ↔
Mitochondrial ROS Striatum, cortex Amplex red assay ↔
22–24 Mn-SOD Striatum WB ↔
CuZn-SOD Striatum WB ↔
Catalase Striatum WB ↔
G6-PDH Striatum WB ↔
PINK1 KO 2 Mitochondrial ROS DCF assay ↔ [104]
PINK1 KO 4 GSH synthetase Striatum, midbrain, cortex 2DGE + MS ↑ in cortex and striatum [28]
Peroxiredoxin 1 Striatum, midbrain, cortex 2DGE + MS ↑ in cortex
Protein oxidation Striatum, midbrain, cortex Oxyblot ↔
PINK1 KO 2-3 4-HAE Left ventricle MDA/4-HAE kit ↑ [105]
8-OHdG Left ventricle 8-OHdG kit ↑
GSH/GSSG Left ventricle GSH/GSSG kit ↓
SOD activity Left ventricle SOD activity kit ↓
Aconitase activity Left ventricle Aconitase activity kit ↓
SNCA KO N.R. Hydroxyl radicals Striatum 4-HBA trapping ↔ [106]
SNCA OExp
A30P
N.R. Oxidized/nitrated α-syn Brain IHC Only OExp stain positive [107]
SNCA OExp
A30P
6–14 Protein oxidation Entire brain 2DGE + WB
↑ (oxidized mitochondrial proteins
Car2, Eno1, Ldh2)
[108]
SNCA OExp
A53T
12 Oxidized α-syn Spinal cord, locus coeruleus IHC OExp stain positive [109]
Nitrated α-syn Pons IHC OExp stain positive
SNCA OExp
A53T
N.R. Mitochondrial DNA damage Brainstem, neocortex, spinal cord TUNEL technique ↑ [110]
Nitrated α-syn Spinal cord IHC OExp stain positive
SNCA OExp
A53T A30P
3, 6 GPx 3 Striatum Microarray ↓ [111]
SOD 2 Striatum Microarray ↓
SNCA OExp
WT
12 Oxidized α-syn Entire brain WB ↑ [112]
Abbreviations: 2DGE: 2D gelelectrophoresis, 2-HBA: salicylate, 4-HNE: 4-hydroxynonenal, 4-HAE: 4-hydroxyalkenal, 8-OhdG: 8-hydroxydeoxyguanosine, α-syn: α-synuclein, GPx: GSH peroxidase, GSH:
glutathion, GSSH: oxidized glutathion, H2O2: hydrogen peroxide, IHC: immunohistochemistry, IF: immunofluorescence, KO: knockout, mo: months, MS: mass spectrometry, OExp: overexpression, PHPA: p-
hydroxyphenylacetate, ROS: reactive oxygen species, SN: substantia nigra, SOD: sodium dismutase, WB: Western blot, WT: wildtype, ↑: increased, ↓: decreased, ↔: not dierent.
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UCP4 and UCP5, comprising mitochondrial uncoupling in
response to Ca2+-induced stress [96].
Furthermore, DJ-1 interacts with DAXX, a protein that
binds to a fas death receptor and activates the JNK apoptotic
pathway. By binding to DAXX, DJ-1 sequesters the protein
into the nucleus and prevents it from gaining access to the
cytoplasm and from inducing apoptosis at the fas death
receptor. DAXX upregulation has been found to occur in
cells that have been treated with H2O2, linking oxidative
stress to this pathway. These data show that DJ-1 is involved
in inactivating the apoptotic JNK pathway that is activated
by oxidative stress, indicating its role in guarding against
oxidative-stress-induced cell death [113].
4.2. Parkin Models. In line with the findings on DJ-1 defi-
cient mice, no significant dierences in protein oxidation
have been found in dierent brain structures of parkin KO
mice at the age of 2, 3, 12, and 22 months [100, 101, 114].
However, when the entire brain was analyzed for protein
oxidation, an increase was described in parkin KO mice at
18 to 20 months [100]. The same pattern was observed for
lipid peroxidation in aged parkin KO mice [100].
Total striatal GSH levels were elevated in parkin KO mice
at the age of 11 months, while no dierences were observed in
GSSG levels [99]. Rodrı´guez-Navarro et al. [102] also noticed
increased total GSH levels in the striatum, midbrain, and
limbic system of young parkin KO mice; however, total GSH
levels were decreased at 24 months old of age in all the brain
regions. No changes were observed in the activity of GSH
reductase, catalase and GPx in the same brain regions when
comparing age-matched parkin KO, but an age-dependent
increase was found for GPx and reductase within the parkin
KO group [102].
It is interesting to note that the endogenous levels of DA
were increased in the limbic regions of the above-mentioned
mutant mice, while the DOPAC/DA and DOPAC/3-
methoxytyramine (3-MT) ratios were also increased. The
increased DA levels and increased DA metabolism to DOPAC
via MAO, an enzyme considered to be mostly intraneuronal,
and to 3-MT via COMT, an enzyme considered mostly
extraneuronal, suggest that parkin dysfunction impairs the
release of DA and increases intraneuronal DA metabolism
via MAO. To determine in which cellular compartment DA
is shifted to intraneuronal oxidation, the turnover of cate-
cholamines after inhibition of their synthesis by α-methyl-
tyrosine (α-MT) was investigated. The rate of depletion of
catecholamines in α-MT-treated animals was similar in both
mutant and WT animals, suggesting that the turnover is
similar in both groups. Since the short-term eects of α-MT
on catecholamines are mostly related to the turnover of the
newly synthesized intracytoplasmic pool of catecholamines,
rather than the vesicular pool of catecholamines, these data
suggest that the increased production of DOPAC in the
absence of parkin is not mediated by changes in DA turnover,
but due to intracytoplasmatic DA being unprotected against
metabolism by MAO. Hence, monoamine metabolism in
parkin mutant mice was shifted towards the H2O2 producing
MAO pathway, with a compensatory increase in GSH levels.
Although there was no evidence for a reduction of nigros-
triatal dopaminergic neurons in the parkin mutant mice, the
level of DA transporter (DAT) protein was reduced in these
animals, suggesting a decreased density of dopaminergic ter-
minals or adaptative changes in the nigrostriatal system.
Such an adaptive change was revealed by Itier et al. (2003)
who noticed reduced amphetamine-induced DA release in
neuronal cultures from parkin mutant mice compared to
WT [99]. A similar decrease in evoked DA release in striatal
slices was demonstrated by Kitada et al. [115]; however,
the levels of total DA and striatal DAT were comparable
between the experimental groups [115]. On the contrary,
another study showed higher striatal levels of DA, DOPAC,
and homovanillic acid (HVA) in parkin KO mice [116].
Similarly, increased DA levels in the midbrain, alongside a
decrease in endogenous DA release after methamphetamine
(METH) challenge shown by ex vivo autoradiography, and
an upregulation of DA D1 and D2 receptor binding in the
striatum were shown in parkin KO mice [117].
A proteomic analysis, performed by two-dimensional gel
electrophoresis coupled with mass spectrometry, revealed
several markers of oxidative stress to be upregulated or
downregulated in either the ventral midbrain, or the striatum
and cortex of parkin KO mice. In the ventral midbrain of
8-month-old parkin KO mice, a decrease in peroxiredoxin
1, 2, 6 and lactoylglutathione lyase was observed [100].
Furthermore, a decreased antioxidant capacity was observed
in the serum of parkin KO mice [100]. Several proteins
involved in detoxification, stress-related chaperones, and
components of the UPS were also altered in parkin KO mice
[101]. These dierences might reflect adaptive mechanisms
aimed at compensating for the presence of ROS and the
accumulation of damaged proteins in parkin KO mice. This
study provides clues into possible compensatory mechanisms
that protect dopaminergic neurons from death in parkin KO
mice and may help to understand the preclinical deficits
observed in parkin-related parkinsonism [101].
No gross mitochondrial abnormalities in striatal mito-
chondria from parkin KO mice were demonstrated, but
reductions in the respiratory capacity were found [100].
Additional findings, which might be related to increased
ROS, are an increased astrogliosis in the striatum and
increased levels of microglial markers in the midbrain of
aged parkin KO mice [102]. Furthermore, in aged parkin
KO mice, higher levels of nitrotyrosine and nitrated α-syn
were found in the SN [103]. However, in another parkin
KO model, immunohistochemical analysis of olfactory bulb,
cortex, basal ganglia, midbrain, and brainstem of α-syn, glial
fibrillary acidic protein, and ubiquitin, as well as staining
with thioflavin S, hematoxylin/eosin, and silver, revealed
no dierences between parkin null mice compared with
WT mice [114, 118]. Only one group demonstrated age-
dependent dopaminergic degeneration in the SN of parkin
KO mutant determined by a significant loss of dopaminergic
neuron terminals in the striatum and a reduction of striatal
DA levels. Furthermore, age-dependent accumulation of
proteinase-K-resistant endogenous α-syn in the SN was
found, which was colocalized with 3-nitrotyrosine (3-NT)
[103]. However, earlier it was demonstrated that the ratio
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of prosurvival/proapoptotic proteins, as measured by the
fraction Bcl2/Bax, is reduced in the striatum and the
midbrain of young mature and of aged parkin KO mice
with respect to their respective age-matched controls. This
was associated with a greater number of apoptotic cells with
fragmented DNA in the striatum and SN of 24-month-old
parkin KO mice than in any other group [102].
4.3. PINK1 Models. Similarly, as with the other mouse mod-
els, no significant dierences in protein oxidation and lipid
peroxidation have been found in dierent brain structures of
PINK1-deficient mice [28, 29]. However, in the left ventricle
of PINK1 KO mice, increased lipid peroxidation and DNA
oxidation were observed [105].
The role of PINK1 in the maintenance of basic functions
of mitochondria was investigated by several groups [30,
119]. In this perspective, PINK1 KO mice did not reveal
any changes in the ultrastructure or the total number of
mitochondria [29, 120]. Nevertheless, some of the functional
aspects of the mitochondria were found altered in PINK1
KO mice. Reduced mitochondrial respiration was shown in
a brain-region-specific manner in young PINK1 KO mice,
with the impairment present in the striatum, which is rich
in dopaminergic nerve terminals, but absent in the cerebral
cortex, suggesting that high concentrations of DA in the
striatum may render the striatum more sensitive to the
loss of PINK1 than in the cerebral cortex [29]. Consistent
with the presence of oxidative stress in the striatum, and
independent of the genotype, an increased lipid peroxidation
was present in the striatal mitochondria relative to cortical
mitochondria [29]. Furthermore, in the striatum of PINK1
KO mice, no dierences in dierent antioxidant proteins
could be observed [27, 29].
However, with a large proteomic screening, increased
levels of GSH synthetase in the striatum and cortex and
increased levels of peroxiredoxin 1 in the cortex were
observed in PINK1 KO mice [28]. Within the left ventricle
of PINK1 KO mice, decreased activities of SOD, and of
mitochondrial and cytoplasmic aconitase were observed,
associated with a decreased ratio GSH/GSSG [105].
Mitochondria isolated from PINK1 KO mice had sig-
nificantly reduced membrane potential [55]. As has been
noted previously, under conditions of oxidative stress,
the cysteines of the mitochondrial permeability transition
pore undergo oxidation, thus increasing the probability
for the pore to open and collapse the transmembrane
potential. In conditions of PINK1 deficiency, the changes in
mitochondrial transmembrane potential are independent of
the mitochondrial permeability transition pore regulation,
suggesting that other pathways are involved [29]. PINK1 KO
mice do not show any loss of dopaminergic neurons and
have normal levels of striatal DA and DA receptors [88, 121].
Although silencing of PINK1 does not cause degeneration,
it induces some functional deficits, such as a decrease in
evoked extracellular striatal DA levels, which may lead to a
decreased activation of postsynaptic DA 1 and DA 2 receptors
and, as a consequence, to defects in striatal plasticity and in
spontaneous locomotor activity [121, 122]. It has also been
observed that silencing of PINK1 expression in mice using
RNA interference did not change the striatal DA content
and the nigral dopaminergic neuron number [123]. These
observations strengthen the hypothesis that PINK1 has a
critical role in DA release and that loss of PINK1 may play
a role in mechanisms preceeding nigrostriatal degeneration.
It has been demonstrated that PINK1 can protect
mitochondria via the activation of mitochondrial chaperones
TRAP-1 and HtrA2. In vitro studies lacking these chaperones,
such as the study by Gautier et al. [29], only support a direct
protective role of PINK1 [29]. The neuroprotective mecha-
nisms of PINK1 might involve the phosphorylation of these
key signaling proteins in pathways governing cell death and
survival. Upon phosphorylation, these proteins may mediate
neuroprotective signals of PINK1 by dierent mechanisms.
Upon phosphorylation, TRAP-1 is activated and blocks
generation of mitochondrial ROS. HtrA2 phosphorylation
protects neuronal cells from undergoing apoptosis induced
by neurotoxins and oxidative stress [124].
Several studies in PINK1-deficient neuronal cells and
fibroblasts from patients carrying PINK1 mutations also
revealed increased levels of mitochondrial ROS and lipid
peroxidation [125]. The oxidative stress observed in these
patients or in PINK1-deficient cells can also result from
reduced antioxidant defense mechanisms. Indeed, Gegg
et al. [126] demonstrated that silencing PINK1 resulted in
decreased cellular levels of reduced GSH, as reduced GSH
levels were decreased in human PINK1 KD cells, as well as
in human fibroblasts derived from PINK1 patients [126].
Mitochondrial Ca2+ overload and a concomitant impaired
buering capacity were also observed due to PINK1 defi-
ciency and appeared to be caused by a defective Na+/Ca2+
antiporter function [27, 65]. An indirect role for PINK1 in
Ca2+ signaling in zebrafish has been proposed [64]. Using
a yeast two-hybrid screen, the interaction of PINK1 and a
Ca2+ sensing molecule, neuronal Ca2+ sensor 1, has been
demonstrated [64]. This sensor may be involved in the
regulation of DA 2 receptor expression [127] and the
release of neurotransmitters [128]. An increased Ca2+-
induced mitochondrial permeability transition was shown
in purified brain mitochondria of PINK1 KO mice [29].
Accumulation of phospho-c-jun in neurons of the SN of
PINK1 KO mice was shown, suggesting that JNK activity
in PINK1 KO mice is increased. Therefore, the increased
mitochondrial Ca2+ sensitivity and JNK activity are early
defects in PINK1 KO mice that precede reduced DA levels
and abnormal DA homeostasis, and that may contribute
to neuronal dysfunction. Dierential gene expression in
the nigrostriatal system of PINK1 KO mice supports early
dopaminergic dysfunction and shows that PINK1 deletion
causes aberrant expression of genes that regulate innate
immune responses [104]. Striatal gene expression profiles
between 2-month-old WT and PINK1 KO mice have been
performed. Several of the upregulated genes encoded stress-
inducible transcription factors of the activating transcrip-
tion factor (ATF,) and AP1 families, including ATF-3, c-
fos, FosB, JunB and Egr-2. ATF3 is induced by multiple
signals, including inflammatory cytokines, DNA-damaging
agents, and physiological stressors. Interestingly, increased
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striatal expression of Fos-related antigens and JunB has been
observed following neuronal injury and degeneration in the
DA system. Moreover, striatal c-fos expression is regulated
by DA and, in the DA-depleted striatum, may be induced via
compensatory supersensitivity of DA receptors [104].
Apart from complex I inhibition, recent genetic data
point to PD-associated genes that are linked with normal
mitochondrial function and resistance against oxidative
stress, such as parkin, PINK1, and DJ-1. All these genes
are believed to play an important protective role within
the mitochondria by preventing mitochondrial dysfunction
mediated by oxidative stress [125]. This protective role
might be mediated by parkin’s ubiquitin ligase function.
Indeed, production of ROS is a physiological consequence
of the mitochondrial respiratory chain, and parkin might
play a role in removing oxidatively damaged proteins that
can impair normal mitochondrial function. However, it is
equally possible that parkin’s protective action may be medi-
ated via its signalling function [24]. DJ-1 can be considered
as a redox-active molecule that can sense oxidative stress via
oxidation of an internal cysteine residue, followed by translo-
cation to the mitochondrial matrix and intermembrane
space [9]. Once localized to the mitochondria, DJ-1 can act
as a molecular chaperone to protect against oxidative stress
[129]. Furthermore, DJ-1 localized in the intermembrane
space can act as a free radical scavenger, preventing the
accumulation of free radicals derived from the mitochondrial
respiratory chain [63].
Interestingly, recent insights indicate the collaboration
of all mitochondrial PD genes, DJ-1, PINK1, and parkin,
in protecting the mitochondria against oxidative stress [7].
Furthermore, parkin and PINK1 seem to act in concert to
mediate the autophagic degradation of terminally damaged
mitochondria, functioning as a global mitochondrial quality
control mechanism [119, 130, 131]. Such a quality control
mechanism is important to the cell, as damaged mitochon-
dria are sensitive to rupture and release of proapoptotic
mediators via a selective form of macroautophagy known
as mitophagy [130], and loss of this protective function
may be an important cause of neurodegeneration in PD,
as neuronal death in PD appears to occur by apoptosis
rather than necrosis [17]. Consistently parkin can partially
compensate for PINK1 loss when being overexpressed [132].
Nevertheless, a recent study demonstrated that even the
inactivation of the genes PINK1, DJ-1, and parkin is
insucient to cause significant nigral degeneration within
the lifespan of the mice, suggesting that these genes may be
protective to external stressors rather than being essential
for the survival of dopaminergic neurons during the normal
aging process [133].
4.4. SNCA Models. Under physiological conditions, there
was no dierence in the basal hydroxyl radical production
in the striata of WT and homozygous SNCA KO mice, sug-
gesting that α-syn deficiency does not aect basal hydroxyl
radical production [106]. As has been noted previously, α-
syn is a specific target of nitration in the SNc of PD patients,
suggesting the role of oxidative damage in the formation
of α-syn inclusions [134]. Similarly, an increased oxidative
damage, as shown by the presence of oxidized and nitrated
α-syn, was shown in mice that overexpress mutant or WT α-
syn [107, 109, 110, 112]. In addition, in the A30P mutant
mouse model, increased levels of oxidized mitochondrial
proteins were found [108], whereas in mice overexpressing
the mutant A53T form of α-syn, increased mtDNA damage
was demonstrated [110]. The presence of mtDNA damage
is possibly related to oxidative stress, since the presence of
nitrated α-syn was shown in the same mouse model [110].
Moreover, in double mutant α-syn transgenic mice,
decreased expression levels of GPx 3 and SOD-2 were
described, yet this still needs to be confirmed at the protein
level [111]. Furthermore, an A53T α-syn transgenic mouse
model was found to have higher DJ-1 levels at 3 months
of age, suggesting an attempt to preserve mitochondrial
function and reduce oxidative burden [55]. Furthermore, it
was shown that α-syn is colocalized with the JNK interacting
protein (JIP). This proposes a protective role for α-syn
against oxidative stress, due to its ability to inactivate the JNK
pathway via upregulation of JIP. The protective activity of
α-syn may be decreased when the protein is mutated, mis-
folded, or aggregated and therefore unable to interact with
JIP [113]. Growing evidence indicates a connection between
α-syn, oxidative stress, and mitochondrial dysfunction in PD
[54, 81]. In this connection, α-syn can bind to mitochondrial
complex I and inhibit its activity, illustrating one way in
which excess α-syn can aberrantly induce mitochondrial
dysfunction [55]. The oxidative events seem to be fairly
target specific, concerning the modified amino-acid residue.
Indeed, for instance, the nitration of tyrosine residues within
the α-syn protein is found to accumulate in the LBs [36].
The main involvement of SNCA in PD is via α-syn
aggregation, as α-syn oligomers are considered as an impor-
tant source of cell toxicity for dopaminergic neurons [129].
Selective damage to both soluble and insoluble α-syn, which
increases the tendency to aggregate, has been demonstrated
in the brains of PD patients [81]. Free radicals may lead
to the stabilization of a toxic protofibril of α-syn, and this
stabilization appears to depend on the oxidative ligation of
α-syn to DA [81]. Furthermore, α-syn is involved in synaptic
vesicle homeostasis and the storage of DA in synaptic vesicles,
and the loss of normal α-syn function following aggrega-
tion can lead to increased levels of oxidative stress [56].
Furthermore, the described mutations reduce the anity
of α-syn for lipids, therefore increasing the cytoplasmic
pools of the protein, and this in turn can be aected by
several mechanisms [23]. Furthermore, it is known that
lipid-bound WT α-syn is a potent inhibitor of phospholipase
D2, an enzyme that hydrolyzes phospholipids, and that is
involved in synaptic vesicle recycling [56]. As a consequence
of the mutations, a decreased phospholipase D2 inhibition
will in turn lead to enhanced and dysregulated synaptic
vesicle recycling and reduced synaptic vesicle formation. The
inability of the neurons to from synaptic vesicles from the
early endosome may result in a decreased number of vesicles
available for DA storage, leading to accumulation of DA
in the cytoplasm [56]. It was shown that toxic oligomeric
aggregates of α-syn can also bind to and form pores in
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the vesicle membrane, thereby releasing the remaining DA
vesicular stores in the cytoplasm [63]. As a consequence,
mutations in SNCA can lead to both loss of normal α-syn
function in synaptic vesicle dynamics, and gain-of function
of toxic α-syn aggregation [56], both pathways leading to
a higher content of cytoplasmic DA, which in turn consid-
erably increases cellular oxidative stress [23]. Mutations in
SCNA have also been shown to have a modulatory action
on tyrosine hydroxylase (TH) activation, inhibit of vesicular
monoamine transporter 2 activity, interact with septin4
[135], and alter the expression of dihydropteridine reductase
[51]. Furthermore, a complex formation with the human
DAT has been shown, thereby inhibiting the uptake of DA
by its transporter [51].
Recently, induced pluripotent stem-cell-derived dopam-
inergic neurons obtained from a PD patient with SNCA
triplication showed increased levels of oxidative stress and
were more sensitive to H2O2-induced oxidative stress [45].
Additionally, α-syn levels increase within the dopaminergic
neurons with aging, an important etiological factor of PD
[24]. These findings and the intrinsic potential for the
oxidative metabolism of DA to generate ROS have suggested
that oxidative stress may be involved in the degeneration of
the dopaminergic neurons in the SNc of PD patients [134].
Altogether, these findings indicate that genetic alterations
in the PD genes parkin, PINK1, DJ-1, and SNCA can
contribute to enhanced levels of oxidative stress. Even though
the precise mechanistic subtleties are yet to be revealed, the
working hypothesis based on the previously presented data is
that they could enhance cellular oxidative stress by contribut-
ing to oxidative stress generating pathways in dopaminergic
neurons, such as improper DA handling, mitochondrial
dysfunction, and neuroinflammation (Figure 1).
5. Gene-Environment Interactions in Mouse
Models of Parkinson’s Disease
Besides the genetic background, environmental factors, such
as environmental toxins or lifestyle factors, may have a role
in PD pathogenesis [24].
5.1. Environmental Toxins. Hints that environmental toxins
might play a role in the molecular pathology of PD first
appeared after the accidental administration of MPTP in
a group of young intravenous drug users, who eventually
developed a clinical phenotype reminiscent of late-stage PD,
albeit in the absence of LB pathology [69]. It was the first
proof that the exposure to an environmental toxin could
produce parkinsonism in humans. MPTP was subsequently
identified as a potent neurotoxin that can easily cross
the blood-brain barrier, being metabolized to 4-phenyl-
2,3-dihydropyridinium ion (MPP+) in astrocytes, a potent
mitochondrial complex I inhibitor, that is then selectively
transported into dopaminergic neurons via DAT, ultimately
leading to cell death via mitochondrial impairment [24].
In addition to MPTP, other environmental toxins, such as
the herbicide paraquat and rotenone have been identified
as contributors to dopaminergic neuronal cell death and
parkinsonism, supporting further the link between environ-
mental exposure to pesticides and a risk of developing PD.
Interestingly, a recent meta-analysis of 19 studies on the
involvement of environmental pesticides in the pathogenesis
of PD found an estimated doubling of the risk to develop
PD [7]. Four individual pesticides were found to increase the
risk of PD: dieldrin, maneb, paraquat, and rotenone [24],
the latter two behaving as mitochondrial toxins, in a similar
manner to MPTP [7].
5.2. Lifestyle Factors. Lifestyle factors and dietary habits have
also been shown to influence the risk of developing PD.
Epidemiological data showing that consumption of coee,
tobacco, and nonsteroidal anti-inflammatory drugs reduces
the risk of PD are intriguing [1, 55]. A high lipid consump-
tion and caloric intake have been investigated as potential
risk factors in PD. This was confirmed by a study showing
that eating foods high in animal fat is associated with
increased risk of PD [136].
5.3. Gene-Environment Interactions. As previously noted, the
current view is that the ethiopathogenesis of PD is fueled
by an interplay of genetic, environmental, and age-related
factors, with gene-environment interactions playing a critical
role [24]. In certain cases, genetic susceptibility is insucient
to lead on its own to PD [24]. For instance, the penetrance
of some monogenic forms of PD is incomplete and variable,
such as the penetrance of the Gly2019Ser mutation in LRRK2
[24]. Therefore, other factors, such as age and environmental
exposure to certain toxins, might contribute to the pathology.
At the same time, the converse is also true, as the risk of
developing PD after toxin exposure also seems to be deter-
mined in part by genetic factors. Indeed, it seems that the
presence of mutations that predisposes to spontaneous neu-
rodegeneration are able to increase the endogenous toxicity
of environmental toxins [24]. Recent studies also suggest that
environmental factors may contribute to neurodegeneration
through the induction of epigenetic modifications, such as
DNA methylation and chromatin remodeling, which may
induce alterations in gene expression [137]. In PD, a direct
relation between epigenetics and neurodegeneration has not
been widely exploited yet [137]. It has been shown that
methylation of the α-syn intron 1 was reduced in DNA
from SN, putamen, and cortex in patients with sporadic
PD. Methylation of this intron region regulates the α-syn
expression in experiments using a luciferase reporter, sug-
gesting that hypomethylation of α-syn intron 1 contributes
to increased expression of α-syn in PD. In turn the toxicity
induced by α-syn can be rescued by administration of
histone deacetylase (HDAC) inhibitors in both cell culture
and a transgenic fruit fly Drosophila model. Furthermore,
HDAC inhibitors may be neuroprotective in dopaminergic
neurons and in rodent models of PD [138]. Epigenetics may
constitute the missing link in the interplay between genes and
environment, despite this, it still remains largely unexplored
[137].
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Figure 1: Pathways leading to oxidative stress in PD and the modulation by PD-related genes. Dierent pathways contribute to high levels
of oxidative stress in dopaminergic neurons, including impaired DA handling (1), mitochondrial dysfunction (2), and neuroinflammation
(3). As further discussed in the text, alterations in PD genes can potentiate all these impairments and, therefore, lead to enhanced levels of
oxidative stress (see Table 2). UPS dysfunction (4), another important pathogenic pathway in PD, can contribute to the damaging eects of
α-syn, due to improper degradation of α-syn mutants or oligomers. Abbreviations: ACO: aconitase, CYT: cytosolic, DA: dopamine, iNOS:
inducible nitric oxide synthase, PHOX: NADPH oxidase, UPS: ubiquitin proteasome system, UCP: uncoupling proteins, VESIC: vesicular.
5.4. Toxin-Induced Models. The classical animal models of
PD are based on the use of neurotoxins that reproduce some
of the pathological and behavioural changes of the disease by
inducing selective degeneration of the nigrostriatal system.
The prototypical toxin-induced PD model is the 6-OHDA
model, which is still the most commonly used procedure
for obtaining PD-like loss of dopaminergic neurons in the
SNc [139]. Until now, the neurotoxicity of 6-OHDA has been
linked to (auto-) oxidation and the formation of quinones,
H2O2 and oxygen radicals, intra- and extracellularly, and to
inhibition of complex I and complex IV of the respiratory
chain. Next to this, it has been shown to induce a massive
release of DA in the extracellular space of the striatum, which
in turn may contribute to oxidative stress. An increased
level of DA may be correlated with an increased DA
metabolism, which in turn may lead to an enhanced basal
production of H2O2 and a depletion of GSH. It has also
been demonstrated that nigrostriatal infusion of 6-OHDA
is associated with an increased inflammatory response,
due to activated microglia, which produce and release a
broad spectrum of free radicals and inflammatory cytokines
[139].
5.5. Genetic Models and Environmental Challenge. To com-
plete our understanding of the genetic contribution to PD, a
full characterization of the genetic architecture of the disease
is needed, together with an exploration to the complex inter-
action between genetic and environmental factors. As the
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current genetic models of PD do not reproduce the complete
disease pattern, the influence of genes, environment, and the
interaction between both on dierent aspects of PD should
be explored through the use of appropriate animal models.
Nevertheless, genetic models can still provide interesting
insights into the role of dierent genes in the pathogenic
pathways of PD.
Integrating the use of neurotoxins, thereby simulating
the environmental etiology, and the genetically engineered
mice models, enables to simulate the gene-environment
interactions that might occur during the development of PD.
Consequently, a literature search was performed for studies
where the susceptibility of genetic PD models to environ-
mental stressors has been investigated (Table 3). Of course,
not all environmental stressors used in the experimental
settings are widely available to human exposure but should
be considered as surrogate environmental stressors, as there
is considerable overlap in pathogenic pathways. For example,
6-OHDA can be used as a surrogate stressor, as it has a similar
mechanism of action as the more common environmental
toxins, such as rotenone and paraquat. Furthermore, to
increase the predictive validity of the animal model, the
main etiological risk factor of PD, namely, ageing, can be
integrated within the model, thereby representing more
realistic conditions.
6. Transgenic Models in Conjunction
with a Neurotoxin
6.1. DJ-1 Mouse Models. DJ-1 KO mice of 2 to 4 months
old were found to be significantly more susceptible to
nigrostriatal deficits following systemic MPTP injection
[140, 141]. Furthermore, in WT mice, adenoviral-mediated
overexpression of DJ-1 blocks MPTP-induced neuronal loss
and protects the animals against neurodegeneration in the
SNc [140, 142]. Consequently, these findings point to a phys-
iological role for DJ-1 in the protection of neurons against
oxidative stress and environmental neurotoxins [140].
However, exposure of MPTP to dierently generated
DJ-1 KO mice resulted in striatal DA depletion with no
dierences in dopaminergic nigral cell loss [141]. Further-
more, enhanced DAT levels in mice deficient in DJ-1 protein
were revealed when the transporter was evaluated in cell
preparations enriched for synaptosomal membranes [141].
The discrepancy with the findings of Kim et al. [140] is likely
due to dierences among the various lines of DJ-1-deficient
mice that dier in their sensitivity to MPTP [140, 141]. One
explanation could be that the C57BL/6 background strain of
the DJ-1 KO mice confers higher sensitivity to MPTP than
the B6/129 background of transgenic animals of Manning-
Bog et al. [140, 141]. Indeed, since a couple of years, several
reasons to avoid the use of MPTP have been proposed,
including its strain-, age-, and gender-dependency in mice
[150, 160–164].
6.2. Parkin Mouse Models. Parkin KO mice of 3 months of
age challenged with the neurotoxins METH or 6-OHDA are
not more sensitive compared to WT mice, as demonstrated
by analysis of striatal DA levels [98]. METH is a toxin that
releases vesicular DA into the cytoplasm and extracellular
space and can inhibit mitochondrial function [98].
These findings suggest that the absence of a robust
parkinsonian phenotype in parkin deficient mice is not
due to the lack of exposure to environmental triggers
with mechanisms of action similar to METH or 6-OHDA.
Nevertheless, parkin-deficient mice could be more sensitive
to other neurotoxins, such as rotenone or MPTP, which have
dierent mechanisms of action [98]. Indeed, overexpression
of parkin in combination with MPTP exposure appears
to provide some protective benefits [142], whereas parkin
delivery rescues α-synucleinopathy in a rat model [89, 142].
6.3. PINK1 Mouse Models. The exposure of mitochondria
isolated from the striatum or the cerebral cortex of aged
PINK1 KO mice to mitochondrial toxins, such as paraquat,
6-OHDA, DA, and rotenone, does not lead to a dierent level
of H2O2 production as in basal conditions [29]. PINK1 KO
mice challenged with a systemic, acute lipopolysaccharide
(LPS) injection and killed 8 hours after LPS administration
demonstrated higher striatal expression levels of IL-1β, IL-
12, and IL-10. Striatal levels of 12 cytokines were not dierent
versus WT without LPS challenge. Furthermore, a tendency
for increased striatal expression of IL-2, IL-4, and TNF-α was
observed after the LPS challenge. No dierences were found
in striatal CD3 expression before and after the LPS challenge.
Isolated and cultured neonatal microglia from forebrain of
PINK1 KO mice were also challenged with LPS. Higher
expression of IL-10 and similar expression of IL-6, TNF-
α, and granulocyte-colony stimulating factor (G-CSF) were
found in cultured microglia after an LPS challenge [104].
In a recently published study, a conditional PINK1 RNA
interference (RNAi) transgenic mouse model was exposed to
paraquat. Mice were exposed to paraquat at the age of 14
days and further at the age of 12 weeks for 3 consecutive
weeks. One week after the last paraquat injection, RNAi-
mediated PINK1 KD was activated by injection with 4-
hydroxytamoxifen to induce Cre activity. At the age of 20
months, significant loss of dopaminergic neurons and loss
of striatal DA was found in these mice [143]. Consistently,
locoregional overexpression of PINK1 protects dopaminergic
neurons from degeneration caused by MPTP [144]. Taken
together, these data reveal an important in vivo role of PINK1
in protecting dopaminergic neurons against toxin-induced
cell death.
6.4. SNCA Mouse Models. As shown by dierent groups,
α-syn-deleted mice are more resistant to MPTP neuro-
toxicity than their WT littermates, as demonstrated via
striatal DA content determination and/or staining of the
nerve terminals and/or dopaminergic nigral neurons [106,
145–149]. However, the intrastriatal administration of 3-
nitropropionic acid resulted in a significant increase in
the striatal hydroxyl radical production in the WT mice,
which was significantly attenuated in heterozygous and
homozygous SCNA KO mice in a dose-dependent manner,
suggesting that α-syn deficiency results in neuroprotection
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Table 3: Gene-environment interactions in transgenic mouse models of Parkinson’s disease.
Model Age (mo.) Marker for susceptibility to oxidative stress Sampled region Technique Outcome (versus control) References
DJ-1 KO 2-3 Lesion after MPTP SN, striatum
TH/DAT IHC,
DA HPLC
↑ [140]
DJ-1 KO 3-4 Lesion after MPTP Striatum
TH WB, DA
HPLC
↑ [141]
DJ-1 OExp N.R. Lesion after MPTP SN TH IHC ↓ [142]
Parkin KO 3 Lesion after 6-OHDA Striatum DA HPLC ↔ [98]
Lesion after METH Striatum DA HPLC ↔
Parkin OExp N.R. Lesion after MPTP SN TH IHC ↓ [142]
PINK1 KO 24
Mitochondrial ROS after paraquat, 6-OHDA, DA,
or rotenone
Striatum, cortex
Amplex red
assay
↔ [29]
PINK1 KO 6 IL-1β, IL-12, and IL-10 after LPS Striatum ELISA ↑ [104]
PINK1 KD 20 Lesion after paraquat SN, striatum
TH IHC, DA
HPLC
↑ [143]
PINK1 OExp 2-3 Lesion after MPTP SN TH IHC ↓ [144]
SNCA KO 2 Lesion after MPTP SN, striatum TH IHC ↓ [145]
SNCA KO 2-3 Lesion after MPTP Striatum DA HPLC ↓ [146]
SNCA KO 2-3 Lesion after MPTP Striatum DA HPLC ↓ [147]
SNCA KO 9 Lesion after MPTP SN TH IHC ↓ [148]
SNCA KO 2-3 Lesion after MPTP SN, striatum
TH IHC, DA
HPLC
↓ [149]
SNCA KO N.R. Lesion after MPTP SN, striatum
DAT IHC, DA
HPLC
↓ [106]
Hydroxyl radicals after 3-NP Striatum 4-HBA trapping ↓
SNCA KO 2-3 Lesion after 6-OHDA SN TH IHC ↓ [150]
Lesion after 6-OHDA Striatum DA HPLC ↔
SNCA OExp A30P 6 Lesion after MPTP SN, striatum
TH IHC, DA
HPLC
↔ [151]
SNCA OExp A30P 3-4, 6–8 Lesion after MPTP SN TH IHC ↑ [152]
Lesion after MPTP Striatum DA HPLC ↔ at 3-4 mo., ↑ at 6–8 mo.
Lesion after rotenone SN, striatum
TH IHC, DA
HPLC
↔
SNCA OExp A53T 2 Lesion after MPTP SN, striatum
TH IHC, DA
HPLC
↔ [153]
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Table 3: Continued.
Model Age (mo.) Marker for susceptibility to oxidative stress Sampled region Technique Outcome (versus control) References
SNCA OExp A53T 9-10 Lesion after MPTP Midbrain DA HPLC ↔ [154]
3-NT after MPTP Olfactory bulb WB ↑
SNCA OExp A53T 2, 12, 23 Lesion after iron and/or paraquat SN TH IHC
↔ at 2 mo. and 12 mo., ↑ at
23 mo.
[155]
2, 23 3-NT after iron and/or paraquat SN TH 3NT IF ↔ at 2 mo., ↑ at 23 mo.
12 Nitrated α-syn after iron and/or paraquat SN TH nSYN IF ↑
SNCA OExp A53T 7 Lesion after LPS SN, striatum TH IHC ↑ [156]
Nitrated α-syn after LPS Midbrain WB
OExp are positive for
nitrated α-syn only after
LPS
SNCA OExp WT or
A53T
3-4 Lesion after paraquat SN TH IHC ↓ [141]
SNCA OExp WT 3-4 Lesion after paraquat SN TH IHC ↔ [157]
SNCA OExp A53T
A30P
2-3 Lesion after MPTP Striatum DAT IHC ↑ [158]
SNCA OExp A53T
A30P
6-7 Lesion after paraquat+maneb SN, striatum
TH IHC, DA
HPLC
↑ [159]
Abbreviations: 2-HBA: salicylate, 3NT: 3-nitrotyrosine, 6-OHDA: 6-hydroxydopamine, α-syn: α-synuclein, DA: dopamine, DAT: dopamine transporter, HPLC: High Pressure Liquid Chromatography, IHC:
immunohistochemistry, IF: immunofluorescence, KO: knockout, KD: knockdown, LPS: lipopolysaccharide, METH: methamphetamine, mo: months, MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, OExp:
overexpression, ROS: reactive oxygen species, SN: substantia nigra, TH: tyrosine hydroxylase, WB: Western blot, WT: wildtype, ↑: increased, ↓: decreased, ↔: not dierent.
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by reducing oxidative stress [106]. Consequently, Klivenyi
et al. [106] concluded that the protective eects of α-syn
deletion were due to reduced hydroxyl radical formation
[106]. One drawback of using 3-nitropropionic acid is its
nonselectivity for dopaminergic neurons. Alvarez-Fischer et
al. [150] checked the susceptibility of SNCA KO mice to 6-
OHDA and found that deletion of α-syn rendered the mice
more resistant to 6-OHDA and suggested that the toxicity
of 6-OHDA was at least partially mediated by α-syn [150].
These findings demonstrate that deletion of α-syn results
in neuroprotection, which might be mediated via inhibition
of ROS formation [106, 150, 165, 166]. Another hypothesis
suggests that aggregated, misfolded, and oxidized α-syn,
released or secreted from dying dopaminergic neurons,
induces ROS formation, providing another mechanism by
which ROS production could be attenuated in α-syn-deleted
mice [150]. Mice overexpressing the mutant α-syn A30P
under the control of a neuron-specific Thy-1 or a TH
promoter are not more susceptible to MPTP compared to
their WT littermates at the age of 6 months old [151]. These
findings are in contrast with the increased susceptibility to
MPTP of α-syn A30P Tg5093 transgenic mice at 6–8 months
of age. Furthermore, in the same mice, the lesion degree was
not dierent from their nontransgenic littermate controls at
the age of 3-4 months and a chronic rotenone treatment did
not result in a dierent lesion degree [152].
Mice overexpressing unilaterally the mutant human α-
syn A53T in the SN are not more vulnerable to MPTP when
compared to control [153]. The authors argue from their
results against a direct function of (mutant) α-syn in oxida-
tive stress or apoptotic pathways [153]. On the contrary,
transgenic mice expressing human A53T α-syn are more
sensitive to the neurotoxicity of MPTP when compared to
non-transgenic littermates. Furthermore, MPTP treatment
of the A53T transgenic mice was associated with a marked
elevation in the 3-NT levels, which colocalized with α-syn
[154].
In another study by Peng et al. [155], the combined
eects of neonatal iron feeding and environmental paraquat
exposure on age-related nigrostriatal degeneration in trans-
genic mice expressing the A53T familial mutant form of
human α-syn was assessed in three age groups, namely, 2, 12,
and 23 months old. Paraquat exposure reduced dopaminer-
gic neurons in all three age groups to the same extent in WT
and A53T α-syn expressing transgenic mice, suggesting that
paraquat toxicity is age-independent [155]. However, by 23
months of age, paraquat induced loss in dopaminergic cell
numbers was more pronounced in those animals that had
previously received elevated oral iron during the neonatal
period, demonstrating that older iron-fed animals are more
susceptible to exposure to the paraquat than younger iron-
fed animals and that paraquat administration accelerates
nigral dopaminergic neuronal loss in these animals as a
consequence of early iron exposure [155]. Furthermore, the
neurodegeneration could be attenuated by a systemic treat-
ment with the bioavailable antioxidant compound EUK-189.
In addition, EUK-189 administration appeared to reduce
the amount of colocalization of nitrated α-syn within the
nigral dopaminergic neurons, suggesting a preeminent role
for oxidative stress in neurodegeneration and impairment
of dopaminergic function in an experimental model of
PD, which combines environmental exposures with genetic
factors known to separately be involved in the disease
[155]. On the contrary, paraquat neurotoxicity assessed in
mice overexpressing α-syn, either the human WT or the
A53T mutant form of the protein, displayed paraquat-
induced protein aggregates, but were completely protected
against neurodegeneration. Furthermore, increased levels of
heat shock protein 70 were found, which could, therefore,
contribute to neuroprotection in the transgenic mice [141].
In young and old double mutant (A53T and A30P)
transgenic mice, the vulnerability against MPTP [158] and
paraquat plus the fungicide maneb [159] was assessed. The
enhanced toxicity of MPTP in the young double mutant mice
could be due to a higher density of the DAT [158]. Double
mutant mice expressing human A53T and A30P mutant
forms of α-syn were more sensitive to paraquat and maneb-
induced toxicity, when compared to mice expressing human
WT alone [159].
In another study, 7-month-old transgenic mice express-
ing the A53T familial mutant form of human α-syn were
injected with LPS. When compared to WT mice, only the
transgenic mice displayed a persistent neuroinflammation,
chronic progressive nigrostriatal degeneration, accumulation
of aggregated, nitrated α-syn, and formation of LB like
inclusions in nigral neurons. In addition, a treatment with
two inhibitors of inducible NOS and NADPH oxidase
blocked the neurodegeneration in LPS-injected transgenic
mice [156].
So how can we interpret the accumulating data on gene-
environment interactions in mouse models of PD? Although
literature findings are not always consistent, most point
towards a consensus, where parkin, PINK1, and DJ-1 are
important in protecting the neurons in the face of oxidative
damage, whereas α-syn seems to play an intriguingly dual
role, enhancing the sensitivity to oxidative stress in con-
ditions of overexpression, and decreasing the sensitivity to
oxidative stress in conditions of deletion (Figure 2). Alto-
gether, there is significant evidence confirming that gene-
environment interactions are relevant to PD pathogenesis,
and that the above-mentioned PD genes are involved in
pathways linking oxidative stress to cell survival.
7. Concluding Remarks
Recent advances in understanding the genetics of PD in
humans, as well as the use of animal models of PD, have
enabled us to make important steps not only in identifying
factors involved in the pathogenesis, but also in determining
how these factors interact [9]. However, the lack of a clear
picture regarding the pathogenesis of PD means that rational
neuroprotective therapies are still missing. Therefore, there
is currently an urgent need for the elucidation of the exact
molecular architecture behind the pathogenesis of PD, in
order to provide sound bases for a rational pharmacological
intervention that can prevent, slow down, or stop the
progressive neuronal degeneration.
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Figure 2: Gene-environment interactions involving oxidative stress
in genetic mouse models of PD. Environmental factors and ageing
converge to induce cellular oxidative stress, and this can either lead
to cell death, or cell survival, based on genetic background. As
shown in various gene-environment interaction studies in mouse
models of PD (see Table 3), the PD genes can tilt the balance either
to cell death, or to cell survival, thereby modulating the survival
of the neurons following oxidative damage. Abbreviations: KO:
knockout, OExp: overexpression.
Not only the genetic findings, but also compelling
data from epidemiological studies, indicate that PD is a
strong candidate for studying gene-environment interactions
[167]. The susceptibility of an individual to develop PD
probably involves a complex interplay of genetic factors,
environmental factors and ageing, with the consequence that
within a population of individuals with PD, considerable het-
erogeneity exists with regard to function of specific cellular
pathways [9]. Despite the importance of this interplay, not
much data are available on gene-environment interaction
studies in animal models of PD. Although dierent genetic
animal models of PD have failed to fully reproduce the
PD pathology, they still provide an interesting platform
to investigate the role of the dierent PD-associated genes
on the integrity of the nigrostriatal dopaminergic and
other neuronal systems. The exposure of animal models
to external stressors may accelerate the disease process and
distinguish them more from animal models that are kept in
well-controlled laboratory conditions away from stressors.
We suggest that challenging genetically engineered animal
models of PD might be of important value to predict
the influences of the genetic alterations on the readouts.
Furthermore, most of the studies that characterize animal
models of PD only take into account the phenotype of the
disease, without considering presymptomatic manifestations
of PD. Investigating pre-symptomatic aspects, such as oxida-
tive stress, might allow a more in-depth characterization of
animal models.
Since biomarkers are important tools to monitor the
disease status of an individual, eorts should be made to
develop, standardize, and harmonize the dierent techniques
to allow experimental studies to be performed across dier-
ent centers ensuring power, allowing replication, and increas-
ing their successfulness. Several promising approaches for
PD biomarkers, such as proteomics, are heading towards
promising directions (reviewed in [168–171]. Furthermore,
it should be emphasized that the detection of more than one
marker for oxidative stress is key, because a single marker
might give misleading results [31]. More eorts should be
made to extrapolate findings from PD patients to animal
models and vice versa. Not only findings, but also the
developed methodologies should be more applicable and/or
easy adjustable for application in both animal models and
PD patient. As mentioned above, it is wellknown that PD
is a heterogeneous neurodegenerative disorder and results
in the occurrence of a variety of symptoms, which forms
the basis for classifying PD patients into dierent subtypes
[1, 172, 173]. Since, the severity and type of the symptoms
among these dierent subtypes may vary from patient to
patient and may likely reflect distinct underlying etiologies,
their identification and biochemical characterization may
facilitate our understanding of their pathogenesis, which
consequently may lead to more tailored therapies [1, 173].
To our knowledge and after extensive literature research, no
data have been found that investigated the dierent subtypes
of PD in terms of impact of oxidative stress and pathogenesis.
Within this review, we focused on the complex interac-
tion and complementary interrelationship between oxidative
stress and neurodegeneration and the possible connection
between oxidative stress and PD-associated genes. Although
not always consistent, literature findings point to an impor-
tant involvement of the PD genes parkin, PINK1, DJ-1,
and SNCA in the oxidative stress pathogenic pathway and
in protection against oxidative stress, confirming again that
oxidative stress is an important pathogenic pathway in PD.
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